Latest News for: multiple myeloma

Edit

Smoldering multiple myeloma: What it is, how it progresses and the latest research

Hastings Tribune 25 Apr 2025
Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms such as bone pain and tiredness ... .
Edit

Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025

Nasdaq Globe Newswire 25 Apr 2025
TARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc ... This novel predictor is designed to identify multiple myeloma patients most likely to benefit from daratumumab. .
Edit

Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025

Pharmiweb 24 Apr 2025
The Amanitin-based ADC candidate HDP-101 is being evaluated in a Phase I/IIa clinical trial for the treatment of relapsed or refractory multiple myeloma ... option for patients with multiple myeloma.
Edit

Bispecifics/Trispecifics Market Poised for Transformative Growth by 2035 – Insights by DelveInsight | Featuring Akeso, ...

GetNews 23 Apr 2025
The bispecifics/trispecifics market is driven by the need for targeted treatments in cancers like ALL, DLBCL, Follicular Lymphoma, Multiple Myeloma, NSCLC, and SCLC ... • DLBCL and Multiple Myeloma ...
Edit

Emotional Purple Power game for West Ottawa soccer as team honors coach Nguyen

Holland Sentinel 23 Apr 2025
PARK TWP ... This year's game had an extra layer of emotion that brought the Panthers together ... "He has always been there ... Hoa was diagnosed with AL amyloidosis and multiple myeloma and recently concluded his first stage of treatments ... This is 100% them.
Edit

Minimal Residual Disease Treatment Market Size in 7MM is expected to grow at a decent ...

GetNews 22 Apr 2025
... myeloma after undergoing autologous stem cell transplant ... According to the statistics published by the American Cancer Society 2022, 34,470 new cases of multiple myeloma in the United States in 2022.
Edit

Desmoid Tumors Treatment Market Size in 7MM is expected to grow at a decent CAGR ...

GetNews 22 Apr 2025
SpringWorks is also evaluating nirogacestat as a potential treatment for patients with ovarian granulosa cell tumors and for patients with multiple myeloma as part of several B-cell maturation agent ...
Edit

TCR Therapy Market Research Report 2025-2035: NY-ESO-1 Target Antigen is Likely to Dominate, Multiple Myeloma ...

Business Wire 19 Apr 2025
Cancer continues to be one of the key areas of research and drug development within the pharmac .
Edit

CAR T-Cell Therapy Market Set for Exponential Growth to USD 129.45 Billion by 2034

Pharmiweb 17 Apr 2025
In July 2024, in an effort to improve the treatment of multiple myeloma, the Multiple Myeloma Research Foundation (MMRF) invested USD 1 million through its Myeloma Investment Fund in Dynamic Cell Therapies' (DCT) cutting-edge CAR T-cell technology.
Edit

GSK wins approval in the UK for blood cancer drug

The Times/The Sunday Times 17 Apr 2025
... and Healthcare Products Regulatory Agency (MHRA) for the treatment of adults with multiple myeloma in combination with an existing drug for patients who have received at least one prior therapy.
Edit

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma (GSK plc)

Public Technologies 17 Apr 2025
Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable.10,11 There are approximately more than 180,000 new cases of multiple myeloma ...
Edit

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma (Form 6-K) (GSK plc)

Public Technologies 17 Apr 2025
Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable.[10],[11] There are approximately more than 180,000 new cases of multiple myeloma ...
Edit

New Real-World Data support effectiveness and tolerability of Pepaxti in heavily pretreated Multiple Myeloma patients (Oncopeptides AB)

Public Technologies 16 Apr 2025
2025-04-16 10.00.00 CEST Oncopeptides AB - Investor News New Real-World Data support effectiveness and tolerability of Pepaxti in heavily pretreated Multiple Myeloma patients ... multiple myeloma (RRMM).
Edit

Global Blood Cancer Treatment Market to Soar Beyond USD 18,729.4 Million by 2035 amid Innovation Surge and Precision Care Revolution | FMI

Pharmiweb 16 Apr 2025
This growth reflects not only rising incidence rates but also the rapid advancements in immunotherapy, precision diagnostics, and personalized treatment protocols transforming how leukemia, lymphoma, and multiple myeloma are managed worldwide.
×